A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : UGT1A9

Search Conditions:
Search Keyword : UGT1A9
Search Method : Exact match.
Research Area:

Abbreviation: UGT1A9
Appearance Frequency: 25 time(s)
Long forms: 7

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
UDP-glucuronosyltransferase 1A9
(10 times)
(8 times)
4-MU (2 times)
CYP3A4 (1 time)
ED (1 time)
2007 Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
uridine diphosphate-glucuronosyltransferase 1A9
(9 times)
(4 times)
SNPs (4 times)
MPA (3 times)
AUC (2 times)
2005 The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
UGT1A7l displays 80% similarity to that encoded by human HP4
(2 times)
(2 times)
--- 1997 Characterization of rabbit UDP-glucuronosyltransferase UGT1A7: tertiary amine glucuronidation is catalyzed by UGT1A7 and UGT1A4.
UDP glycosyltransferase 1 family, polypeptide A9
(1 time)
(1 time)
BMP4 (1 time)
CycD (1 time)
FAM3D (1 time)
2004 Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR.
uridine diphosphate glucuronosyltransferase 1 family-polypeptide A9
(1 time)
(1 time)
HCC (1 time)
HFSR (1 time)
SNPs (1 time)
2012 Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
uridine diphosphateglucuronosyltransferase family 1 member A9
(1 time)
(1 time)
ABCB1 (1 time)
AR (1 time)
HET (1 time)
2019 Acute rejection in kidney transplantation and the evaluation of associated polymorphisms (SNPs): the importance of sample size.
uridine glucuronosyltransferase 1A9
(1 time)
Drug Therapy
(1 time)
AEs (1 time)
MMF (1 time)
MPA (1 time)
2008 Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.